SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Blixt A) srt2:(2005-2009)"

Sökning: WFRF:(Blixt A) > (2005-2009)

  • Resultat 1-10 av 10
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Niklasson, B, et al. (författare)
  • Prenatal viral exposure followed by adult stress produces glucose intolerance in a mouse model.
  • 2006
  • Ingår i: Diabetologia. - : Springer. - 1432-0428 .- 0012-186X. ; 49:9, s. 2192-2199
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS/HYPOTHESIS: It has been suggested that the uterine environment may influence metabolic disease occurring later in adult life, and that adult stress may promote disease outcome. Using a mouse model, we tested whether in utero exposure to Ljungan virus (LV) followed by adult exposure to stress produces diabetes. The influence of the timing of viral exposure over the course of pregnancy was also tested. MATERIALS AND METHODS: Pregnant CD-1 mice were exposed i.p. to LV on pregnancy days 4, 8, 12 or 17. Adult male mice from these pregnancies were stressed by being kept in shared cages. Stress only, LV exposure in utero only, and no-stress/no virus exposure groups were also followed. Outcome variables included bodyweight, epididymal fat weight, baseline glucose, glucose tolerance tests (60 and 120 min) and serum insulin. RESULTS: We demonstrated that male mice developed a type 2-like diabetes, including obesity, as adults if infected during pregnancy with LV. Diabetes at the age of 11 w
  •  
2.
  • Winblad, Bengt, et al. (författare)
  • Donepezil in patients with severe Alzheimer's disease : double-blind, parallel-group, placebo-controlled study
  • 2006
  • Ingår i: The Lancet. - New York : Elsevier. - 0140-6736 .- 1474-547X. ; 367:9516, s. 1057-1065
  • Tidskriftsartikel (refereegranskat)abstract
    • Background The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer's disease. Its efficacy in severe dementia has not been assessed and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer's disease, by focusing primarily on cognition and activities of daily living.Methods We did a 6-month, double-blind, parallel-group, placebo-controlled study in 248 patients with severe Alzheimer's disease (mini mental state examination score 1-10) who were living in assisted care nursing homes ran by trained staff in Sweden. We assigned patients oral donepezil (5 mg per day for 30 days then up to 10 mg per day thereafter, n=128) or matched placebo (n=120). Our primary endpoints were change from baseline to month 6 in the severe impairment battery (SIB) and modified Alzheimer's Disease Cooperative Study activities of daily living inventory for severe Alzheimer's disease (ADCS-ADL-severe). We analysed outcomes for patients with data at baseline and at one or more other timepoints (modified intent-to-treat population) with last observation carried forward used to replace missing data.Findings 95 patients assigned donepezil and 99 patients assigned placebo completed the study. Patients treated with donepezil improved more in SIB scores and declined less in ADCS-ADL-severe scores at 6 months after initiation of treatment compared with baseline than did controls (least squares [LS] mean difference, 5.7,95% Cl 1.5-9.8; p=0.008, and 1.7, 0.2-3.2; p=0.03, respectively). The incidence of adverse events was comparable between groups (donepezil 82% [n=105] vs placebo 76% [n=91]), with most being transient and mild or moderate in severity. More patients discontinued treatment because of adverse events in the donepezil group (n=20) than in the placebo group (n=8).Interpretation Donepezil improves cognition and preserves function in individuals with severe Alzheimer's disease who live in nursing homes.
  •  
3.
  •  
4.
  • Ryazhkin, A. V., et al. (författare)
  • Local atomic structure of Fe-Ni/V multilayer nanostructures : EXAFS spectroscopy and synchrotron radiation data
  • 2008
  • Ingår i: Journal of Structural Chemistry. - 0022-4766 .- 1573-8779. ; 49:1, s. S129-S137
  • Tidskriftsartikel (refereegranskat)abstract
    • Fe, Ni, and V K EXAFS spectroscopic experiments were carried out at the European Synchrotron Radiation Center (ESRF) in the fluorescent mode on the 26 angstrom line with the use of the [(Fe82Ni18)(5)/V-6](25) and [(Fe82Ni18)(10)/V-6](25) samples of multilayer nanoheterostructures prepared by magnetron spraying (at Uppsala University). The partial interatomic distances were determined by the regularization technique. The existing distortions of the bee lattice in (Fe82N18)/V multilayer nanostructures depend strongly on the thickness of the ferromagnetic layers of the permalloy and also affect vanadium layers.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  • Stowell, Sean R, et al. (författare)
  • Galectins-1, -2 and -3 exhibit differential recognition of sialylated glycans and blood group antigens
  • 2008
  • Ingår i: Journal of Biological Chemistry. - : ASBMB. - 1083-351X. ; 283:15, s. 10109-10123
  • Tidskriftsartikel (refereegranskat)abstract
    • Human galectins have functionally divergent roles, although most of the members of the galectin family bind weakly to the simple disaccharide lactose (Galss1-4Glc). To assess galectin-glycan interactions in more detail, we explored the binding of several important galectins (Gal-1, Gal-2, and Gal-3) on a glycan microarray containing hundreds of structurally diverse glycans. All three galectins exhibited unique glycan binding characteristics. Only Gal-1 and Gal-2 bound complex-type N-glycans and extended core 1 O-glycans with high affinity, while Gal-2 and Gal-3, but not Gal-1, bound A and B blood group antigens. Gal-2 failed to recognize any sialylated glycans regardless of linkage, whereas Gal-1 and Gal-3 bound a2-3, but not a2-6 sialylated glycans. All galectins showed higher binding to sulfated glycans relative to unsulfated ones. Each galectin exhibited higher binding for glycans with poly-N-acetyllactosamine (PL) sequences (Galss1-4GlcNAc)n when compared to N-acetyllactosamine (Galss1-4GlcNAc) in the microarray. However, only Gal-3 preferred PL when assessed by solution-based surface plasmon resonance. Removal of the terminal galactose residue in PL abrogated its recognition by Gal-1 and Gal-2 while having no substantial effect on Gal-3 recognition, demonstrating that Gal-3 recognizes internal N-acetyllactosamine units. These results provide novel insights into the functional constraints of glycan recognition by each galectin and underscore the basis for differences in biological activity.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 10
 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy